Category: Becton Dickinson & Co.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, Guidant Corp.
, Johnson & Johnson
, Smith & Nephew
, Stryker Corp.
, Valeant Pharmaceuticals
, Allergan Inc.
Becton Dickinson plans to cut the debt load from its $12 billion acquisition of CareFusion by some $1.4 billion after realizing it has more cash available that it thought.
Becton Dickinson's $12.2 billion bid for device maker CareFusion clears the required waiting period under U.S. anti-trust regulations.
Here's a look at some of the top legal news stories for medical device companies this week: BD owes $340m to Retractable Technologies in anti-trust case; Feds indict Vascular Solutions, CEO over Vari-Lase; Federal jury begins deliberations in Boston Scientific mesh trial; Boston Scientific ordered to pay $26.7 million over mesh devices; Judge dismisses 76 Ethicon pelvic mesh lawsuits in Texas
A federal judge orders Becton, Dickinson & Co. to pay $340 million to Retractable Technologies for BD's claim that it had the 'world's sharpest needle.'
Sales and earnings rise during the fiscal 1st quarter for CareFusion as it prepares to be absorbed by Becton, Dickinson & Co.
CareFusion (NYSE:CFN) ended its last fiscal quarter as a public company on a strong note, posting earnings growth of 2.8% on a top-line gain of 11.1%.
Becton, Dickinson & Co. beats Wall Street's forecast with its fiscal 2015 sales and earnings, sending share prices up in pre-market training today.